Alzamend Neuro, Inc. Receives Nasdaq Delisting Notice: Key Information for Investors

Summary of Key Points

• Alzamend Neuro, Inc. (NASDAQ: ALZN) received a notice from Nasdaq regarding non-compliance with continued listing standards.
• The company’s stockholders’ equity as of January 31, 2026, was approximately \$2.2 million, below the required minimum of \$2.5 million for continued listing on the Nasdaq Capital Market.
• The notice does not have an immediate effect on the listing or trading of ALZN shares. The shares will continue trading on Nasdaq for now.
• Alzamend will need to submit a plan to regain compliance and has up to 180 days to resolve the issue, subject to Nasdaq’s approval.
• If the company’s plan is not accepted or compliance is not achieved, Nasdaq may initiate delisting proceedings.
• In case of a delisting determination, Alzamend may appeal the decision, which would temporarily halt any suspension or delisting action.
• The company is classified as an emerging growth company under SEC rules and has not elected to use an extended transition period for accounting standards.

Detailed Analysis and Implications for Shareholders

On March 20, 2026, Alzamend Neuro, Inc., a Delaware corporation, disclosed that it received a letter from the Nasdaq Listing Qualifications staff. The letter indicated that the company’s reported stockholders’ equity in its Form 10-Q for the fiscal quarter ended January 31, 2026, was \$2.2 million, falling short of the \$2.5 million threshold required by Nasdaq Listing Rule 5550(b)(1) for continued listing on the Nasdaq Capital Market.

This is a material event for shareholders and potentially price-sensitive, as failure to maintain Nasdaq listing standards can have significant impacts, including:

• Reduced liquidity for ALZN shares if the stock is delisted
• Possible negative perception among investors, partners, and customers
• Potential difficulty in raising capital or attracting institutional investors

The company clarified that the notice does not immediately affect the trading of its common stock, which will continue to trade under the symbol “ALZN” on Nasdaq. However, the company must submit a plan to Nasdaq describing how it will regain compliance with the minimum equity requirement. There is no assurance that Nasdaq will accept the plan or, if accepted, that Alzamend will regain compliance within the allotted 180-day period.

If the compliance plan is not accepted or if Alzamend fails to achieve compliance, Nasdaq could provide formal notice that the shares will be delisted. In such a scenario, the company has the right to appeal, which would temporarily stay any suspension or delisting action until the hearing process concludes and any extension period granted by the panel expires.

Forward-Looking Statements and Risks

The report contains forward-looking statements regarding the company’s ability to regain compliance, appeal potential delisting, and other related matters. These statements are not guarantees of future performance and are subject to risks and uncertainties, including:

• Continued losses and negative cash flow
• Need for additional funding, which may not be available
• Lack of significant revenue from its core business
• An evolving business model
• Risks disclosed in prior SEC filings, such as the Form 10-K filed on July 14, 2023

Investors should be aware that failure to regain compliance, or any negative outcome from Nasdaq’s review or appeal process, could result in delisting and materially impact the share value.

Regulatory and Corporate Facts

• Alzamend Neuro, Inc. is a Delaware corporation headquartered in Atlanta, GA.
• Its common stock (\$0.0001 par value) trades under the symbol ALZN on the Nasdaq Capital Market.
• The company is classified as an emerging growth company and has not opted for extended transition periods for complying with new accounting standards.
• No written, soliciting, or pre-commencement communications are noted in the filing.

Conclusion

This notice of potential delisting is a key development for Alzamend Neuro, Inc. shareholders. The outcome of the compliance plan submission and any related appeals will be closely watched, as the company’s Nasdaq listing status remains uncertain. Investors should monitor further announcements and consider the risks associated with possible delisting, which can have major effects on share liquidity and valuation.

Disclaimer: This article is based on public SEC filings and is intended for informational purposes only. It does not constitute investment advice. Investors should conduct their own research and consult with financial advisors before making investment decisions. The information provided may contain forward-looking statements subject to risks and uncertainties. Alzamend Neuro, Inc. may update or change its disclosures, and investors should monitor all official company filings for the latest information.

View Alzamend Neuro, Inc. Historical chart here